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CObjectives: To systematically review and synthesize the literature
on the costs of atrial fibrillation (AF) with attention to study design
and costing methods, geography, and intervention approaches.
Methods: A systematic search for previously published studies report-
ing the costs for AF patients was conducted. Data were analyzed in
three steps: first by evaluating overall system costs; second by evalu-
ating the relative contribution of specific cost components; and third by
examining variations across study designs, across primary treatment
approach, and by geography. Finally, a specific review of the treatment
costs associated with anticoagulation treatment was examined given
the clinical importance and attention given to these costs in the
literature. Results: The literature search resulted in 115 articles. On
eview of the abstracts or full text of these articles, 21 articles met all
tudy criteria and reported on health system AF-related direct costs. A
urther six articles focused exclusively on anticoagulation costs for pa-
ients with AF. The overall average annual system cost across 27 esti- O
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al So
doi:10.1016/j.jval.2011.09.009ates obtained from the literature was $5450 (SD  $3624) in 2010
anadian dollars and ranged from a low of $1,632 to a high of $21,099.
bout one-third of these costs could be attributed to anticoagulation
anagement. The largest cost component was acute care, followed by
utpatient and physician and then medication-related costs.
onclusion: AF-related medical costs are high, reflecting resource-in-
ensive and long-term treatments including anticoagulation treat-
ent. These costs, accompanied with increasing prevalence, justify
ncreased attention to the management of patients with AF. Future
tudies of AF cost should ensure a broad assessment of the incremental
irect medical and societal cost associated with this diagnosis.
eywords: atrial fibrillation, cost analysis, cost of illness, direct cost,
ystematic review.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Atrial fibrillation (AF) has been described as a silent epidemic
[1]. Silent because although patients with AF experience signif-
icant morbidity, many patients with AF are asymptomatic when
first detected, and an epidemic because population-based stud-
ies have highlighted a rapid rise in the incidence of this condi-
tion with forecasts of 6 million Americans living with this con-
dition by 2050 [2]. Because AF is directly correlated to advancing
age [3,4], aging populations and increases in the prevalence of
other known predisposing risk factors, such as hypertension [5],
are contributing to increases in AF prevalence internationally,
raising the concern of a major public health crisis and crippling
health-care costs [6,7].
The economic burden of AF is nontrivial. Cost-of-illness
studies have identified annual AF-related costs in 2005 of $6.65
billion in the United States and £459 million in the United King-
dom [8,9], constituting a considerable proportion of a compara-
ble estimate for all cardiovascular disease (e.g., $45.5 billion in
2005 in the United States [10]). It is important to provide a broad-
* Address correspondence to:Walter P.Wodchis, Health Policy Man
College Street, 4th Floor, Toronto, ON M5T 3M6 Canada.
E-mail: walter.wodchis@utoronto.ca.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.based assessment of economic cost associated with AF and to
gain an understanding of its main drivers. Many studies have
examined costs by using different sources of data and different
methodologies. For example, cost-effectiveness studies have
compared AF therapies (pharmaceutical rate or rhythm man-
agement and surgical ablation). While occasionally using local
prices, these latter studies often use economic models popu-
lated with utilization data from a particular study in the litera-
ture, sometimes with insufficient attention to the representa-
tiveness of the assumptions. Others have used surveys,
administrative data, or patient-reported data to estimate care
costs. A systematic review of these costing studies would be partic-
ularly useful to payers, decision makers, and researchers to under-
stand both the economic burden of AF and also how these costs vary
across treatment modalities to identify potential economic impacts
resulting from changes in practice. The objective of the present re-
search was therefore to systematically review and synthesize the
literature on the costs of AF. While such reviews have been con-
ducted for diseases such as dementia [11], diabetes [12], and cardio-
vascular disease [13], there is no synthesis for AF.
ent & Evaluation, Faculty of Medicine, University of Toronto, 155
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Literature review
A systematic search for previously published articles reporting the
costs for patients with AF was conducted from the following da-
tabases: OVID (MEDLINE), EMBASE, and the Cochrane Library us-
ing “atrial fibrillation” subject heading and then “health care cost”
or “cost” or “economic” or “economics” as subject headings. We
limited the search to English language articles published between
1996 and February 2010, updated to January 2011. Articles were
excluded if the cost data covered a period of less than 1 year, if the
article did not provide any new cost information (e.g., summary of
results already reported elsewhere), or if costs were not reported
specifically for patients with AF. To enable comparable costs and
an analysis of cost drivers, studies had to include costs for acute
care and costs for at least one of medication, outpatient, or physi-
cian treatment. To ensure that comparable data could be ex-
tracted from studies with a variety of different study designs, a
final inclusion criterion required that cost data be reported in a
way that could be expressed as a per-person per-year basis. Ab-
stracts were screened by one author for possible inclusion or ex-
clusion before retrieving full-text versions of the publications.
Once retrieved, the full text was scanned to ensure that it met
inclusion criteria. References were further examined to identify
additional relevant articles.
Data abstraction
Using a standardized data abstraction form, data extracted from
each eligible article included the country, currency and year of
cost data, study design, number of patients, primary treatment
intervention, total costs, direct and indirect costs, breakdown of
cost components where available, and data sources.
Standardization of cost data
Most study costs were reported as per-person per-year costs, and
this was adopted as the standard by which study data were com-
pared. Where necessary, cost data reported in each article were
converted to reflect average costs per-patient per-year during the
study period. These annualized costs were then converted to 2010
Canadian dollars first by converting the currency to Canadian dol-
lars in the period of study by using the purchasing power parity for
the year of cost data [14] and then by converting costs to 2010 by
using the Canadian health-care services price index [15]. Annual
costs were available in all except seven articles where only multi-
year cost data were available (e.g., a total cost of $25,623 over a
lifetime of 4.6 years [16]). In the latter cases, the present value cost
was divided by an annuity factor over the same time period and
adjusted by using the discount rate specific to each study.
Analysis
Data were analyzed in three steps: first by evaluating overall sys-
tem costs; second by evaluating the relative contribution of spe-
cific cost components (i.e., acute and other institutional settings,
physician, laboratory,medications, other); and third by examining
variations across study designs, across primary treatment ap-
proach (rhythm, rate, or surgical ablation procedures), and by ge-
ography. Finally, a specific review of the treatment costs associ-
ated with anticoagulation treatment was examined given the
clinical importance and attention given to these costs in the liter-
ature.Results
The literature search resulted in 115 articles (including six added
with the update to 2011). On review of the abstracts or full text of
these articles, 28 were excluded because they did not report cost
data and 33 were excluded because they focused on costs over a
period of less than 1 year or did not include physician, outpatient,
or medication costs. The majority of the latter articles examined
costs associated with a single hospital stay. A further 18 articles
were excluded because they summarized data that were already
reported in another study (typically by the same author), 9 were
excluded because per-patient per-year costs could not be mea-
sured by using the reported data (most commonly because the
data were reported as part of a cost-utility study). Twenty-one
articles met all study criteria and reported on health system AF-
related costs. A further six articles identified in the review focused
exclusively on anticoagulation costs for patientswith AF, four pro-
viding full system costs and two focusing primarily onmonitoring
costs.
System-wide cost studies
Full-year system costs were available from 21 articles inclusive of
hospital, physician, and drug costs. One article reported cost esti-
mates for five different countries, one reported estimates for two
countries, and another provided estimates for both a multicenter
and a single-center cohort. Eight other articleswere cost-effective-
ness studies and provided cost estimates for more than one treat-
ment strategy. Four articles compared rate and rhythm strategies
while six offered comparisons between pharmaceutical manage-
ment and ablation procedures. In total, cost estimates for pharma-
ceutical rhythm or rate management treatment strategies were
either combined or not separately identified in 15 articles. To en-
able comparisons across all estimates, a combined “study” cost
(for all treatment strategies) was calculated by using the total re-
ported average cost in 9 instances. We were therefore able to ex-
tract a total of 27 different combined “study cost” estimates of the
health system cost associated with treating patients with AF over
the course of 1 year of treatment and a total of 16 treatment-
specific estimates including five rhythm-specific, four rate-spe-
cific, and seven ablation-specific cost estimates.
Cost summary
Table 1 presents annualized costs grouped by study design and
ordered by year of reported cost data. Costs are AF-related except
where noted to be either indeterminate or represent all direct
medical costs for patients with AF. The overall average annual
system cost across the 27 (combined-treatment) study-cost esti-
mates obtained from the literature shown in Table 1 was $5450
(SD  $3624) in 2010 Canadian dollars. The median was $4979 (in-
terquartile range $3413–$6371), suggesting a small positive skew
among cost estimates.While these costs are substantial, they rep-
resent only about one-quarter of the entire health system costs for
patients with AF. Three articles estimated the entire system cost
for all care for patientswith AF. Costs for allmedical treatment (AF
and non-AF related) were reported to be $25,715 in a privately
insured population [18] and $39,877 for Medicare patients in the
United States [17] while annual individual costs for stroke patients
with AF was estimated at $20,023 in Germany [24] (all estimates
reported in 2010 Canadian dollars).
A review of studies by methodological approach
Methodological differences across studies were a primary deter-
minant of the types of costs included and therefore the final cost
estimates. Most studies employed the perspective of the health
system payer and included only direct medical costs, while a few
Table 1 – Summary of AF-related direct medical health system costs by treatment.
Ref. Author Publication year Study type Cost year Country Average cost Medical management Surgical ablation
Rhythm Rate Combined*
1 Stewart et al. 2004 Population 2000 UK 6422 6422
17 Wolf et al. 1998 Cohort— Admin (Medicare) 1991 USA 3888 3888
18 Wu et al. 2005 Cohort— Admin 2002 USA 21,099 21,099
19 Kim et al. 2009 Cohort— Admin 2007 USA 8354 8354
20 Rohrbacker et al. 2010 Cohort— Admin 2008 USA 4979 4979
21 Weerasooriya et al. 2003 Cohort— COCAF (Model) 2001 France 3340 4178 2502
22 Le Heuzy et al. 2004 Cohort— COCAF 2001 France 6469 6469
23 Reynolds et al. 2007 Cohort— FRACTAL 2002 USA 7358 7358
24 Bruggenjurgen et al. 2007 Cohort— Berlin Acute Stroke Study 2005 Germany 5060 5060
25 Jonsson et al. 2010 Cohort— Primary data 2005 Sweden 3059 3059
25 Jonsson et al. 2010 Cohort— Primary data 2005 Germany 3936 3936
26 Ringborg et al. 2008 Cohort—Euro Heart Study 2006 Greece 2308 2308
26 Ringborg et al. 2008 Cohort— Euro Heart Study 2006 Italy 5075 5075
26 Ringborg et al. 2008 Cohort— Euro Heart Study 2006 Poland 1632 1632
26 Ringborg et al. 2008 Cohort— Euro Heart Study 2006 Spain 3485 3485
26 Ringborg et al. 2008 Cohort— Euro Heart Study 2006 Netherlands 3255 3255
27 Lumer et al. 2002 Trial—CTAF 1995 Canada 2336 2336
28 Hagens et al. 2004 Trial— RACE 2000 Netherlands 4109 3731 4487
29 Pietrasik et al. 2007 Trial—HOT CAFÉ 2002 Poland 3575 4815 2335
16 Marshall et al. 2004 Trial— AFFIRM 2003 USA 8644 9654 7663
30 Goldberg et al. 2003 Single center 2001 USA 6320 6320
21 Weerasooriya et al. 2003 Single center— Model 2001 France 2669 2929 2409
21 Weerasooriya et al. 2003 Cohort— COCAF— Model 2001 France 3340 4178 2502
31 Moeremans et al. 2000 Model 1998 France 4932 4932
32 Chan et al. 2006 Model 2004 USA 6697 6819 5621 7651
33 Khaykin et al. 2007 Model (CARAF Trial) 2005 Canada 6175 5812 6537
34 Khaykin et al. 2009 Model (RAAFT Trial) 2005 Canada 5674 5656 5691
35 McKenna et al. 2009 Model 2005 UK 4299 3486 5111
All figures represent average per-patient per-year annualized costs in 2010 Canadian dollars.
AF, atrial fibrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of RhythmManagement; CARAF, Canadian Registry of Atrial Fibrillation; CTAF, Canadian Trial of Atrial Fibrillation; COCAF,
Cost of Care inAtrial Fibrillation; FRACTAL, Fibrillation Registry Assessing Costs, Therapies Adverse events and Lifestyle; HOTCAFÉ, How to Treat Chronic Atrial Fibrillation; RAAFT, Radiofrequency
Ablation versus Antiarrythmic Drug Therapy as First-line Treatment; RACE, RAte Control versus Electrical cardioversion.
* Combined costs reported for unspecified treatment in study; all costs specific to AF except Stewart et al. [1], Le Heuzey et al. [22], Ringborg et al. [26], Lumer et al. [27], and Hagens et al. [28] who
used patient reports that may have included non-AF treatment costs.
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243V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 4 0 – 2 4 8included additional economic costs in a partial societal perspec-
tive. For cost comparisons, we included only direct health-care
service costs because these were available in all studies and
describe additional productivity and patient time costs where in-
cluded. Five broad types of study designs were reported on AF-
related costs: 1) one population study that provided national cost-
of-illness estimates extrapolated from surveillance and survey
data; 2) multicenter cohort studies based either on administrative
or on prospectively collected utilization data; 3) trial-based stud-
ies; 4) single-center cohort studies; and 5) economic modeling
studies. Study results and methods are examined within each
study design because studies in each category typically employed
similar types of data sources for utilization and cost data and pro-
vide directly comparable data analyses.
Population studies
One study measured representative population costs for AF at a
national level undertaken from the perspective of the UKNational
Health Service [1]. It used age-sex–specific population prevalence
rates of AF from three cross-sectional UK studies to extrapolate to
the entire UK population in 1995 and updated to 2000. A variety of
assumptions were made to estimate AF-related costs for primary
and specialist physician, outpatient clinic visits, and drug pre-
scriptions, while administrative databases were used to count
acute hospitalizations with a recorded AF diagnosis and subse-
quent admissions to long-term care (LTC).
Cohort studies
Four cohort studies used primarily administrative data. Wolf and
colleagues [17] provide the largest andmost representative cohort
tudy comparingMedicare patients hospitalized with a cardiovas-
ular diagnosis with and without AF. This provided an estimate of
he incremental cost of AF in an older cohort with a heart condi-
ion other thanAF. Importantly, this study used linked claims data
o estimate the incremental costs in acute, postacute care (LTC),
ome care, physician, and outpatient hospital costs. Three US
tudies used proprietary health insurance claims data. Wu and
olleagues [18] examined health system costs for a non-Medicare
population in 2002. They reported average costs for patients with
AF that were $21,099 (per-patient per-year in 2010 Canadian dol-
lars) higher than average costs for patients without AF. A similar
more recent study compared costs for AF patients with costs for
non-AF patients after matching on demographic variables and
found an incremental cost of $4979 for AF [20]. The latter studies
also reported substantial productivity and disability claims costs.
Kim and colleagues [19] reported annual costs of $8354 for pri-
vately insured patients treated with rhythm control medications
based on claims that had an associated AF diagnosis. Five other
cohort studies collected primary prospective data. The Cost of
Care in Atrial Fibrillation (COCAF) study in France provided a large
representative cohort of 671 patients treated by 82 cardiologists
and followed for an average of 1 year [22]. The study provided a
broad perspective of health costs including patient productivity
costs and separately estimated the cost drivers. While detailing
the sources of cost estimates, little information was available to
assess themethods used to collect utilization and other cost driver
data, leaving uncertainty about the specificity (to AF) and the com-
prehensiveness of the estimates. These data were later reana-
lyzed, extrapolated to 10-year costs, and reported stratified by ab-
lation versus medical management with different estimates
reported [21]. The Fibrillation Registry Assessing Costs, Therapies
Adverse events and Lifestyle (FRACTAL) was a North American
study with cost data for 973 patients enrolled through 17 partici-
pating centers [23]. Utilization data were recorded during patient
interviews conducted at 3, 6, 12, 18, 24, and 30 months while cost
data were based on Medicare reimbursement rates. This study
was able to obtain very detailed information about specific tests,treatment, and medications received by patients and to estimate
the primary cost drivers specifically related to AF recurrence. The
Euro Heart Survey on AF was the largest prospective cohort study,
involving 5333 patients in 35 European countries [26]. Based on
patient-reported health-care utilization data collected in case re-
ports completed at 1-year follow-up, and using local prices, this
study reported annual direct and indirect (patient) costs for the
five countries with the largest contributing samples (costs in-
cluded all potential AF-related events including all cardiovascular
hospitalizations). In the Berlin Acute Stroke study, the incremen-
tal impact of AF on costs for patients with stroke was estimated
including a broad assessment of health system and productivity
costs [24]. A final recent article reported AF-specific and total di-
rect medical and indirect costs in Germany and Sweden based on
self-reported surveys from patients and their physicians [25]. This
article included extensive patient-reported nonmedical and indi-
rect productivity costs.
Trial-based studies
The Canadian Trial of Atrial Fibrillation (CTAF) was a random-
ized controlled trial (RCT) comparing amiodarone to alternative
antiarrhythmic therapies (sotalol or propafenone) [27]. Patient-
reported health-care utilization data were collected at 3-, 6-,
and 12-month follow-up with discharge summaries obtained
for hospitalized patients. Total annual physician, medication,
and hospital costs were reported for patients with AF with hos-
pital and pharmaceutical costs specific to AF treatment but in-
cluded outpatient visits that may not have been specific to AF.
The RAte Control versus Electrical cardioversion (RACE) study
was an RCT with 428 patients in the Netherlands [28]. Hospital,
physician, medication, and testing utilization data were col-
lected on the basis of patient reports during study visits at 1, 3,
6, 12, 24, and 30 to 36 months while patient’s own expenses for
professional, nonprofessional, and personal lost-time costs
were collected by using self-administered patient question-
naires. Based on self-administered patient questionnaires,
non-AF treatment costs may have been included. The How to
Treat Chronic Atrial Fibrillation (HOT CAFÉ) was a smaller mul-
ticenter RCT in Poland with 205 enrolled patients who were
assigned to rhythm- or rate-control treatment arms [29]. One-
year costs were based on utilization data collected during fol-
low-up visits and using prices reported from the specific study
sites where patients were treated. Physician visit costs were
based on the national health-care fund rates, and pharmaceu-
tical costs were based on retail prices. Using an intention-to-
treat principle, there were no reported cardioversion attempts
in the rate-control group and the (high) cost of cardioversion,
universally provided to the rhythm treatment group, was
largely responsible for higher costs in the latter cohort. Higher
costs for rhythm treatment were also reported in the US Atrial
Fibrillation Follow-up Investigation of Rhythm Management
(AFFIRM) trial [16]. The latter study provided robust analysis
based on a large population of 4060 patients, an average 3.5-year
follow-up period, with detailed microcosting based on costs
from representative centers and applied to utilization data col-
lected at patient follow-up visits.
Single-center studies
There were two single-center studies, both examining surgical
ablation treatment. The first study followed 33 patients who
underwent radiofrequency catheter ablation with a question-
naire at 1 and 3 years posttreatment [30]. All billing records
including hospitalizations, clinic visits, medications, and emer-
gency department visits and including physician costs for the 3
years prior and posttreatment were compared. Even with 17 of
33 patients requiring a second ablation procedure for recurrent
AF, costs were significantly lower after ablation and 27 of the 33
244 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 4 0 – 2 4 8patients were AF-free after 3 years. The authors did not however
report on the outcomes or costs of 31 patients who were also
referred to the center but did not (for unknown reasons) receive
ablation treatment. In another single-center trial, 20 patients
who had undergone radiofrequency ablation were contacted by
telephone to determine treatment prior to ablation and to re-
cord the frequency of emergency department and physician vis-
its and hospital admissions (costs may have included non-AF-
related events) [21]. Patient records were also reviewed and
merged with patient-reported data. The average follow-up time
for patients was 32 weeks, with subsequent medical treatment
costs including medications modeled/projected to 10 years.
Modeling studies
One decision-analytic model was built to reflect practice in
France including both rhythm and rate control and using a
5-year time horizon [31]. Management costs included detailed
cost and utilization ofmedications, different tests and interven-
tions, and acute and other related costs for AF, as well as AF-
related stroke and congestive heart failure costs. Additional
sensitivity analyses and stratifications examined differences in
cost for paroxysmal and persistent AF and different rates of
anticoagulation among other outcomes. The average distribu-
tion of costs among cost components across studies is shown in
Figure 1.
All other modeling studies were used to examine the cost-
effectiveness of surgical ablation compared with medical man-
agement (rate or rhythm control, often unspecified). Two of
these were from Canada, one represented data for the United
States, one for the United Kingdom, and one for France. Data
from the Canadian Registry of Atrial Fibrillation (CARAF) were
used to estimate treatment factors such as medications, as well
as the proportion of patients treated using rate and rhythm
strategies [33]. Lacking Canadian observed health utilization
data, however, the authors here used French data from Moere-
mans and colleagues’ study [31] (reported above) combined with
authors’ estimates of testing rates for international normalized
ratio (INR), digoxin and thyroid tests, and applied Canadian
prices. Various scenarios of low- and high-cost estimates for
ablation and medical treatment were then compared over a 12-
Physician, 6%
Pharmacy, 13%
Rehabilitation*, 1%
Long-Term 
Care†, 1%
Home Care‡, 4%
Outpatient, 18%
Acute, 55%
Fig. 1 – Distribution of total system costs for patients with
atrial fibrillation. Note: Percentage figures represent
average of costs based on studies. *Rehabilitation included
in only one study and amounted to 13%; †Long-term care
included in three studies averaging 7% in those studies;
‡Home care included in three studies averaging 16%. Other
cost centers were based on 11 reported results. See Table 2
for full details.year period. A second study by the same authors used data from
the randomized trial of Radiofrequency Ablation versus Antiar-
rythmic Drug Therapy as First-line Treatment of symptomatic
atrial fibrillation (RAAFT) [34]. A decision tree structure was
used with a 2-year time horizon. This trial provides more robust
utilization data but found high costs in the medical treatment
arm primarily due to cross-over of 18 of 37 patients initially
randomized to medical treatment into the ablation treatment
arm in the second year of the study. Chan et al. [32] used a
decision-analytic model to estimate lifetime cost-effectiveness
of left atrial catheter ablation compared with amiodarone and
rate control therapy in a hypothetical Medicare cohort. Their
costs included drug therapy, physician and clinic visits, hospital
costs, and anticoagulation and stroke costs. A UK study in-
cluded both a systematic review and a meta-analysis to develop
parameters for another decision-analytic model of radiofre-
quency catheter ablation compared with antiarrhythmic medi-
cations [35]. This study provides a very detailed cost and prob-
abilistic outcome structure and is the only study that provided
separate estimates stratified by risk of stroke, which is an im-
portant driver in the total future cost estimates related to AF. A
final study examined the cost-effectiveness of alternative abla-
tion treatments (“cut and sew” maze, high-intensity focused
ultrasound, and percutaneous) performed concomitantly with
coronary artery bypass graft surgery or valve replacement/re-
pair in patients with AF [36]. This study provided very high es-
timates of success and few reablations compared with other
studies. Costs included medications, hospital procedures, and
stroke-related acute and follow-up costs. No AF-specific fol-
low-up costs by physicians or other providers were included.
Contribution of specific cost components
Ten of the 21 articles also provided detailed cost breakdowns for
three or more of the following cost centers (number of studies
reported in parentheses): acute (10), rehabilitation (1), long-term
care (3), outpatient and physician visits (10), medications (9) [1,17–
19,22,24,25,27,28]. Five of these studies reported AF-specific direct
medical costs while all reported total costs for patients with AF.
These studies are presented in Table 2 and are used to describe the
main cost drivers of AF systemcosts.Where articles did not clearly
report a method for identifying AF-specific costs, the results were
assumed to be reflective of total direct medical costs for patients
with AF. The levels of acute care costs varied considerably but
commonly dominated other cost drivers in studies considering
AF-specific costs, or full-system costs. When included, rehabilita-
tion, LTC, and home-care costs were substantial. The RACE study
in theNetherlands reflected a rather differentmodel of care in that
country, with just 31% of all costs incurred in acute care while 45%
were associated with home care [28]. Still, the total costs in RACE
trial were not on average substantially lower than those in other
studies reporting detailed cost breakdowns.
Variations in AF costs
We also evaluated patterns of average reported AF cost estimates
across studies grouped by study design, country of origin, and
primary treatment approach (rate, rhythm, or ablation). Model-
based estimates from five studies averaged $5555, two single-cen-
ter articles’ estimated annual costs averaged $4495, while the four
trial-based estimates averaged $5166. The five studies based on
administrative data (population and cohort studies) provided the
highest estimated costs for patients with AF, averaging $8948 per-
person per-year ($8762 excluding LTC and home care costs from
Stewart et al. [1] andWolf et al. [17]). Eleven cohort estimates with
primary data collection provided an average estimated cost of
$4089 ($3895 excluding LTC, rehabilitation, and home care from
Bruggenjurgen et al. [24]). Most comparative (cost-effectiveness)
Table 2 – AF-Related and total system direct costs for patients with AF.
Ref. First author System cost Acute care Rehabilitation LTC Home care Outpatient* Physician Pharmacy
AF-Related (only) direct costs for patients with AF
17 Wolf 3,888 3,001 300 89 113† 611
24 Bruggenjurgen 5,060 2,790 417 550 1,162 19 85 36
18 Wu 21,099 12,804 888 5,458 1,948
19 Kim 8,354 5,247 2,037 1,071
25 Jonsson (Sweden) 3,059 2,460 321 278
25 Jonsson (Germany) 3,936 3,694 29 214
27 Lumer‡ 2,336 1,221 1,132 960
Average % included§‡ (average all) (69%) 8% (1%) 9% (3%) 13% (4%) 14% (12%) 14% (6%) 13% (11%)
Total system direct costs for patients with AF
1 Stewart‡ 6,422 4,956 545 335 245 341
17 Wolf 39,877 24,013 2,888 2,184 1,259 9,533
22 Le Heuzey 6,469 3,391 645 581 1,486
18 Wu 25,715 14,031 1,058 7,642 2,983
24 Bruggenjurgen 20,023 11,733 2,646 743 2,371 238 888 1,407
25 Jonsson (Sweden) 3,953 2,808 613 533
25 Jonsson (Germany) 5,547 4,181 56 1,310
26 Ringborg (Greece) 2,308 592 1,311 62 343
26 Ringborg(Italy) 5,075 2,989 1,431 74 582
26 Ringborg (Poland) 1,632 1,094 289 40 208
26 Ringborg (Spain) 3,485 1,659 1,190 62 573
26 Ringborg (Netherlands) 3,255 1,402 1,342 96 415
27 Lumer‡ 4,156 3,025 1,132 960
28 Hagens 4,109 1,278 1,856 409 238 328
Avg. % included§ (average all) (57%) 13% (1%) 6% (1%) 21% (4%) 18% (18%) 8% (6%) 14% (13%)
AF, atrial fibrillation; LTC, long-term care.
* Outpatient includes laboratory tests and emergency visits where reported and includes physician fees for Kim et al. [19], Jonsson et al. [25] and Lumer et al. [27].
† Patients with AF had lower average outpatient costs.
‡ Estimates for outpatient care in Lumer et al. [25] may have included non-AF visits. Only AF pharmacy costs were reported. Stewart et al. [1] estimated that $1335 of the $4956 in acute costs were
attributable to a primary diagnosis of AF but did not provide AF-specific costs for other cost centers.
§ Average % included was calculated as the average of the percentage distribution of costs using only studies with reporting data (this assumes other studies would have had the same average
proportion; (average all in parentheses) show value average including zero reported costs (assuming zero-costs studies where costs were not included).
 Burggenjurgen et al. [24] also reported lost productivity valued at an additional $5303 per AF patient per year; Hagens et al. [28] identified additional nonmedical patient costs of $2071; Ringborg
et al. [26] reported patient lost-work costs ranging from $66 in Poland to $657 in the Netherlands.
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In addition to the health system costs, many of the prospective
cohort and trial-based studies also reported estimates of indi-
rect costs including patient travel costs and lost wages, ranging
from 2% of total costs in Spain [26] to 35% in The Netherlands
[28]. Productivity costs were estimated in cohort studies of em-
ployment-based administrative data [18,20] and patient-re-
ported data [22,24,26].
Regional results
Studies of system costs were conducted in 11 different countries,
with the United States dominating with eight studies. Nine differ-
ent European countries provided 16 estimates of system cost. The
European average was $3977 ($3809 excluding LTC, rehabilitation,
andhome care fromStewart et al. [1] and Bruggenjurgen et al. [24]),
three Canadian estimates averaged $5335, with a US average of
$8417 ($8369 excluding LTC and home care from Wolf et al. [17]).
These estimates obscure additional variation: a single-center
study in France [21] estimated annual system costs as $2669 while
the COCAF estimate was $6469 [22].
Treatment-specific results
Several studies compared treatment approaches. There were five
estimates of annual costs for rhythm treatment that averaged
$5835 while the four estimates for rate treatment averaged $5027
and seven estimates of ablation costs averaged $5191. Fifteen
studies that reported only combined average treatment costs re-
ported an average of $5418.
Anticoagulation
In addition to the system cost data, six studies focused on antico-
agulation treatment specifically or primarily in an AF patient pop-
ulation including costs for acute care, physician visits, medica-
tions, and warfarin monitoring (INR testing). Four were decision
models while the remaining studies drew data from a single-cen-
ter and one multisite study. Canada and the United States were
each represented in two modeling studies with cohort studies
based in US and UK settings. The presence of anticoagulation-
specific studies highlights the importance and magnitude of this
clinical issue in AF.
The total average cost of anticoagulation treatment across
these studies was $2225, amounting to more than one-third of the
total AF-related health-care costs (Table 3). Regier and colleagues
[37] compared self- versus physician-managed anticoagulation
therapy in the province of British Columbia while Mittman and
Table 3 – Total and cost driver data for anticoagulation in p
Ref. Author Total Acute P
41 Abdelhafiz and Wheeldon 444 128
38 Mittman et al. 2068 1602
37 Regier et al. 1849 993
39 Sorensen et al.* 3074 2189
39 Sorensen et al.* 2783 1863
39 Sorensen et al.* 2432 1481
39 Sorensen et al.* 2923 2300
Average 2225 1508
Average %† 68%
All figures represent average per-patient per-year annualized costs.
AF, atrial fibrillation; INR, inernational normalized ratio.
* Sorensen’s estimates are provided under four scenarios of real-worl
derived from Menzin et al. [40] and not reported separately. Follow
costs ranging from $168 to $218 and combined laboratory and phys
† Percentage calculated as average of distribution within each reported escolleagues [38] focused on comparing the costs associatedwith the
varying bioavailability of warfarin products in an Ontario popula-
tion. Both included medication costs for warfarin, physician over-
sight and INR testing, and hospital costs for stroke and bleed
events. Sorensen and colleagues’ [39] articlewas innovative in that
it estimated the cost-effectiveness of warfarin contrasting trial-
based versus “real-world” assumptions about adherence and time
in therapeutic range. Cost estimates for medications and INR test-
ing were drawn from Menzin et al. [40] and included physician
osts, with medications accounting for about one-third of the
osts. The final single-center study similarly included costs for
edications, monitoring costs (including INR fees and overhead
osts), and adverse events (bleeds) but not stroke [41].
Conclusions
AF-related medical costs are high, reflecting resource-intensive
treatments including anticoagulation treatment. These costs, ac-
companiedwith increasing prevalence, justify increased attention
to the management of patients with AF.
Twenty-one articles were identified in the literature as report-
ing annual AF-related costs for treatments provided to patients
with AF. These studies identify substantial costs for AF at both the
individual and population levels. Because of the high cost of acute
care, any hospitalization was the most important determinant of
total costs. The few studies that included other institutional set-
tings (rehabilitation and LTC) identified substantial costs for these
care settings, leading to relatively higher cost estimates. Antico-
agulation management was a significant cost driver due in part to
medications and INR testing but mostly attributable to acute care
utilization for both stroke and bleed events. A few studies included
patient-borne costs and demonstrated substantial productivity
loss in younger cohorts and in time costs for all patients associated
with primary care and specialist visits as well as for INR testing
and other laboratory tests.
The results reported here are comparable to other systematic
reviews of costs for other conditions. A similar review of the liter-
ature on cardiovascular diseases found even greater heterogeneity
in studies (partially due to a less stringent inclusion criteria) [13]. It
reported comparable direct costs for cardiovascular disease rang-
ing from $4,543 to $23,544 per-patient per-year in 2010 Canadian
dollars. Johnsson and Wimo’s [11] study of dementia costs in
Europe estimated direct medical costs averaging $7,552 in 2010
Canadian dollars and nonmedical costs averaging $22,872. Our es-
nts with AF.
acy Laboratory (INR) Physician All follow-up
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247V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 4 0 – 2 4 8timates for AF fall within these ranges, highlighting the burden of
AF among high-cost illnesses.
Converting costs from original studies to a common annual
per-patient health system cost does not result in perfectly compa-
rable costs across individual studies. The data reported here arise
from studies in many different countries over the past 15 years.
The standardization is consistent with recommended guidelines
[42,43], similar studies in the literature [11–13], and the methods
used in the literature summarized here. In spite of the differences
in exact study design, country, and year of study, when standard-
ized to a common comparison measure (2010 Canadian dollars),
these results provide both a range and a reasonable overall base-
line estimate of the annual costs of managing patients with AF in
a generic Western medicine context. These data are particularly
useful in decision models for identifying the burden of illness as-
sociated with AF and for examining potential cost impacts of
changes in clinical practice. This study contributes to the litera-
ture by providing clinicians, decision makers, and researchers
with a range of estimates that can be used as inputs to decision
models and for sensitivity analysis and as a reference regarding
the representativeness of cost estimates.
Some studies excluded from this review provide other useful
cost information. For example, Coyne and colleagues’ [9] popula-
ion studywas based on nationally representative samples of hos-
ital, physician office, and emergency department databases
cross the United States. They estimated both primary AF-related
cute hospital costs and incremental AF costs for hospitalizations
here AF was not the primary diagnosis, enabling a robust mea-
urement of AF-attributable AF costs. However, this studywas not
ncluded because visits were counted but not the population rep-
esented by these visits and costs could not be converted to a
er-person basis. In addition, outpatient costs were based on very
arge extrapolations (175 physician visits in the database were ex-
rapolated by using database sample weights to nearly 5 million
ational visits) withoutmuch regard for the confidence associated
ith such large extrapolations, a recognized limitation with this
ype of study [44]. Other examples of potentially relevant studies
ocused exclusively on hospitalization costs [45], or patients’ own
osts [46], or excluded hospitalizations [47]. In addition, somenon-
nglish language studies may have provided useful results but
ere not included because we could not assess the validity of the
stimates [48,49].
The estimates arising from studies included in this review ap-
ear to be sensitive to study design and data collection approaches
s well as underlying assumptions about treatment effectiveness.
or example, while ablation studies have often found this surgical
ntervention to be cost-effective, the results are highly dependent
pon the uncertain proportion of ablations that are fully success-
ul in the first procedure. Goldberg and colleagues [30] note that
heir estimate of procedural ablation costs weremore than double
omparedwith prior estimates because of reablation costs needed
or 50% of their patients. A recent systematic review found that
ingle procedure success rate of ablation without additional ther-
py was 57% [50]. Rhythmmanagement was generally reported to
emore expensive than ratemanagement. However, Kim and col-
eagues [19] highlighted a high rate of discontinuation (over 75%)
of rhythm control therapy within the first year of treatment initi-
ation. In addition to the AF-treatment uncertainty, the success of
anticoagulation depends heavily upon the uptake of (warfarin)
treatment and time in therapeutic range, both of which are sec-
ondary to prescribing practices and to patient adherence to
complex, costly, and time-consuming monitoring activities.
The major clinical consequence of AF is stroke, accounting for
about 20% of all strokes [51,52]. Furthermore, strokes occurring
in the setting of AF are fatal in 20% of patients and disabling in
60% [53]. To reduce the nearly fivefold increase in stroke risk
among patients with AF, these patients require long-term anti-coagulation treatment that is cumbersome to the patient, re-
source-intensive to the system, and also associated with a risk
of adverse bleeding events.
An additional insight raised by the literature included in this
synthesis is the heterogeneity in treatment pathways (and care
sites) across studies. Better analyses to identify which patients
might be most appropriate for ablation versus other treatment
strategies and who should be targeted for anticoagulation are also
necessary. The management of patients with AF is complex.
Guidelines directed toward helping clinicians choose themost ap-
propriate care for patients with AF, involving a choice between
rate control medications, rhythm control medications, or surgical
catheter-based ablation approaches, and combinations of these
strategies, are currently confusing.
Treatment costs inmany studies did not differentiate between
AF treatment strategies while a number of studies directly com-
pared various combinations of rate, rhythm, and ablation treat-
ments. The literature reviewed here does not resolve the cost-
effectiveness of the various treatment strategies, and ranges of
per-patient per-year costs are largely indistinguishable. Perhaps
this is due in part to the continued heterogeneity in the treatment
strategies currently practiced with patients with AF. This is evi-
dent in multiple studies demonstrating the lack of standardized
approach to the acute management of AF including in emergency
departments where most patients with AF present[54,55].
Study quality also varied considerably. Although methods
were not the focus of ourwork (as, e.g., in Clabaugh andWard [44]),
we found that studies included in this review varied in the num-
ber, type, and categorization of cost components, and often lacked
specificity in the exact methods used for identifying AF-specific
costs. No study provided a complete societal perspective including
all productivity, nonmedical, and patient-borne costs. Most stud-
ies included in this review identified a representative sample of
patients with current AF rather than following patients through a
natural disease history for a specific presentation from first diag-
nosis. Care costs for patients with AF were compared with pre-AF
treatment costs in only one study [30].
While not obviating the need for primary cost data in future
trials, the costs reported in this review offer a range of current and
comparable estimates that should be useful to decision makers
and researchers concerned with the costs of AF. The costs also
highlight the importance for attention to improve management
and reduce adverse events in the AF population.
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